New insights of liquid biopsy in ovarian cancer
- 29 September 2022
- journal article
- Published by Heighten Science Publications Corporation
- Vol. 5 (1), 001-011
- https://doi.org/10.29328/journal.jgmgt.1001007
Abstract
Through the development of new analysis technologies, many issues regarding the approach to tumoral diseases have been elucidated. With analytical assays developed in the last years, various omics technologies have evolved in such a manner that the characteristics of tumor cells and products can be evaluated (assessed) in the bloodstream of cancer patients at different times. Ovarian Cancer (OC) is one of the most difficult to diagnose umors, with low survival rates due to the high heterogeneity of these diseases that are distinct in terms of etiology and molecular characteristics, but which simply share an anatomical appearance. Recent findings have indicated that several types of ovarian cancer classified into different histotypes are in fact derived from non-ovarian issues and share few molecular similarities. Within this context, ovarian cancer screening and diagnosis can be made through the evaluation of circulating tumor cells in peripheral blood using liquid biopsy technologies. Advances in the study of various molecules analyzed by liquid biopsy have shown that elucidation of intratumoural and intertumoural heterogeneity and spatial and temporal tumor evolution could be traced by serial blood tests rather than by histopathological analyses of tissue samples from a primary tumor. Therefore, evaluation of some molecules such as circulating tumor cells (CTC), circulating tumor DNA (ctDNA), circulating cell-free RNA (non-coding and mRNA, extracellular vesicles), tumor-educated platelets or different miRNAs using liquid biopsy could lead to improvement of patient management.Keywords
This publication has 97 references indexed in Scilit:
- An integrated encyclopedia of DNA elements in the human genomeNature, 2012
- Ovarian Cancer Development and MetastasisThe American Journal of Pathology, 2010
- Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: Evidence supporting a mesothelial-to-epithelial transitionGynecologic Oncology, 2010
- The RNA-induced Silencing Complex: A Versatile Gene-silencing MachineOnline Journal of Public Health Informatics, 2009
- Circulating microRNAs as stable blood-based markers for cancer detectionProceedings of the National Academy of Sciences of the United States of America, 2008
- Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancerProceedings of the National Academy of Sciences of the United States of America, 2008
- Isolation of rare circulating tumour cells in cancer patients by microchip technologyNature, 2007
- MicroRNA Signatures in Human Ovarian CancerCancer Research, 2007
- Ovarian Cancer Metastasis: Integrating insights from disparate model organismsNature Reviews Cancer, 2005
- Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast CancerJournal of Clinical Oncology, 2005